Research & Education

EGFR TKI Therapy for Advanced Stage NSCLC: Patient Selection and Treatment Options

Tuesday, December 8, 2015 at 9 p.m. EST - Recording Available
 Anne Tsao  

Anne S. Tsao, MD
Associate Professor
Director, Mesothelioma Program
Director, Thoracic Chemo-Radiation Program
University of Texas
M.D. Anderson Cancer Center
Department of Thoracic/
Head & Neck Medical Oncology

Ramaswamy Govindan, MD - Program Chair
Co-Director, Section of Medical Oncology
Professor of Medicine
Division of Oncology
Washington University School of Medicine

Name of Reviewer(s): 

              

Fred Hirsch, MD, PhD –Speakers Bureau/Advisory Board: Astrazeneca, Genentech, BMS, Lilly and Abbvie.

 

Name of Planner(s): 

 

     Deb Whippen-Nothing to Disclose

 

Name of Activity: 

 

EGFR TKI Therapy for Advanced Stage NSCLC: Patient Selection and Treatment Options

Date of Activity:

 

12/08/2015

Faculty/Speaker(s):

Financial DISCLOSURES

 

Moderator – Ramaswamy Govindan, MD –Pfizer: Advisory Board, Celgene: Advisory Board, AztraZeneca: Advisory Board, INC Research: Consulting, AbbVie: Consulting, Advisory Board and Honorarium, MSK: Advisory Board.

Speaker- Anne S. Tsao, MD

Advisory Board for: Boehringer-Ingelheim, Genentech, Roche, Eli Lilly, Seattle Genetics, Medimmune, Bristol-Meyers Squibb, Novartis and Merck.

Research Funding from: Medimmune, Merck, Genentech, Eli Lilly

Type of Activity: 

 Live Course

  Internet Live Course (Webinar)XXXX

 Internet Enduring Material

Are there Commercial Supporters for this activity?

          No

If yes, please list:

 

IASLC continues the Lung Cancer  LIVE WEBINAR featuring Dr. Anne S. Tsao.

This program will review the role of EGFR tyrosine kinase inhibitors (TKI) in EGFR mutated NSCLC. The most common types of EGFR mutations and their clinical outcomes/sensitivity to EGFR TKIs will be evaluated. A discussion on the use of frontline EGFR TKIs versus maintenance therapy in this population will be undertaken.

After viewing this session attendees will:

  • Identify the latest updates on the clinical outcomes for patients who have EGFR mutant NSCLC (del exon 19, L858) and are treated with erlotinib/gefitinib and afatinib.
  • Recognize the role of CO1686 and AZD9291 in EGFR T790 mutants and learn about studies evaluating these agents in the frontline setting.
  • Discuss the advantages and disadvantages of frontline EGFR TKI usage versus chemotherapy while awaiting test results and then maintenance EGFR TKI.
  • Manage the newest EGFR TKI agents that are in clinical trials at this time.

Following the presentation, there will be ample time for discussion and a question/answer session. Attendees will be able to submit questions and comments to Dr. Tsao via Internet chat.

This CME live webinar series is designed to meet the educational needs of healthcare professionals who diagnose and treat patients with lung cancer, including medical oncologists, thoracic surgeons, pulmonologists, radiation oncologists, radiologists, pathologists and advanced practice nurses and physicians' assistants.

 

CME INFORMATION:

Financial/Commercial Relationships DISCLOSURES

A Conflict of Interest (COI) is created and exists when individuals in a position to control the content of CME, or their spouses/partners, that have a relevant personal financial relationship within the past 12 months with a commercial interest that produces, markets, re-sells, or distributes health care goods or services consumed by, or used, on patients that benefits the individual in any financial amount and therefore, may bias their opinions and teachings. This may include receiving a salary, royalty, intellectual property rights, consulting fee, honoraria, ownership interest (e.g., stocks, stock options or other ownership interest, excluding diversified mutual funds), or any other financial benefit. Financial benefits are usually associated with roles such as employment, management position, independent contractor (including contracted research and clinical trials), consulting, speaking and teaching, membership on advisory committees or review panels, board membership, and other activities for which remuneration is received or expected. 

 This IASLC CME educational activity was planned and developed to: uphold academic standards to ensure balance, independence, objectivity, and scientific rigor; adhere to requirements to protect health information under the Health Insurance Portability and Accountability Act of 1996 (HIPAA); and, include a mechanism to inform learners when unapproved or unlabeled uses of therapeutic products or agents are discussed or referenced.

IASLC CME assures that the planners/reviewers/authors/faculty/moderators/peer reviewers et. al. conflicts of interest  were identified, reviewed and resolved from all individuals involved in the development  or able to influence and control the content of this CME activity; IASLC CME assures that disclosure is given prior to an educational activity being delivered to learners.  Any individual who failed or refused to disclose relevant financial relationships was disqualified from this CME activity and removed from any of IASLC CME activity presentation.

All commercial relationships and conflicts of interest that are identified are thoroughly vetted by IASLC Ethics Committee, CME Subcommittee, and Independent reviewer. COI will be evaluated by the Board of Directors of the IASLC for fair balance, scientific objectivity of studies utilized in this activity, and patient care recommendations. IASLC CME is committed to providing its learners with high-quality CME activities and related materials that promote improvements or quality in health care and not a specific proprietary business interest of a commercial entity.

CREDIT STATEMENT

IASLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

IASLC CME designates this Internet Live Course activity for a maximum of 1 AMA PRA Category 1 Credits™.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

GOAL & PURPOSE

This program will review the role of EGFR tyrosine kinase inhibitors (TKI) in EGFR mutated NSCLC. The most common types of EGFR mutations and their clinical outcomes/sensitivity to EGFR TKIs will be evaluated. A discussion on the use of frontline EGFR TKIs versus maintenance therapy in this population will be undertaken.

TARGET AUDIENCE

This CME live webinar series is designed to meet the educational needs of healthcare professionals who diagnose and treat patients with lung cancer, including medical oncologists, thoracic surgeons, pulmonologists, radiation oncologists, radiologists, pathologists and advanced practice nurses and physicians' assistants.

DISCLAMER

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Thank you for your participation.

DOWNLOAD RECORDING

IASLC financial/Commercial Relationships and Conflicts of Interest Policy

IASLC Honoraria Policy

IASLC Commercial Support Agreement (LOA)

IASLC Lung Cancer Grand Rounds webinars will continue throughout 2015. The goal is to hold one program monthly. Participants who complete a pre-and post-test along with an evaluation will receive 1 AMA PRA Category 1 CreditTM for each completed webinar.

If you are interested in obtaining the CME Credits for these sessions you must indicate this when you register for the program. CME credit is only available to attendees of the live webinar. 

Location Local time Time zone UTC offset
New York (U.S.A. - New York) Tuesday, December 8, 2015 at 9:00:00 PM EST UTC-4 hours
Denver (U.S.A. - Colorado) Tuesday, December 8, 2015 at 7:00:00 PM MST UTC-6 hours
London (United Kingdom - England) Wednesday, December 9, 2015 at 2:00:00 AM BST UTC+1 hour
Rome (Italy) Wednesday, December 9, 2015 at 3:00:00 AM CET UTC+2 hours
New Delhi (India - Delhi) Wednesday, December 9, 2015 at 6:30:00 AM IST UTC+5:30 hours
Moscow (Russia) Wednesday, December 9, 2015 at 4:00:00 AM MSK UTC+3 hours
Shanghai (China - Shanghai Municipality) Wednesday, December 9, 2015 at 9:00:00 AM CST UTC+8 hours
Sydney (Australia - New South Wales) Wednesday, December 9, 2015 at 8:00:00 AM AEST UTC+10 hours
Tokyo (Japan) Wednesday, December 9, 2015 at 10:00:00 AM JST UTC+9 hours
Corresponding UTC (GMT) Wednesday, December 9, 2015 at 2:00:00 AM     

How to use the Time Zone Converter